Hande KURTULGAN KÜÇÜK, Oğuz KARAHAN, Umut Serhat SANRI, Ahmet Turhan KILIÇ, Nurkay KATRANCIOĞLU

PAI-1 4G/4G gene polymorphism is associated with higher serum lipid level in Turkish population.

Amaç. PAI-1 geni protrombotik gen grubunun bir üyesidir. PAI-1 4G/5G polimorfizmindeki 4Galleli yuksek plazma PAI-1 düzeyi ve artmış tromboz riski ile birliktedir. Diğer yandan literatürdebazı popülasyonlarda, 4G alleli ile aterojenik lipid düzeyleri arasında ilişki bulunduğunu iddiaeden makaleler bulunmaktadır. Ancak, Türk popülasyonunda lipid düzeyleri üzerine 4G allelininetkileri hakkında detaylı bilgi bulunmamaktadır. Bu çalışmada, sağlıklı Türk bireylerinde plazmalipid düzeyleri ile PAI-1 4G/5G gene polimorfizminin korelasyonunu araştırmayı amaçladık.Yöntem. Retrospektif olan bu çalışmada, hastanemizin ve tıbbi genetik bölümünün veri tabanıkullanıldı. 55 yaşından büyük bireyler çalışmaya alınmadılar. Katılımcılardan hiç biri herhangi birtedavi almamaktaydı. İzole PAI-1 4G/4G gen polimorfizmi bulunan 50 kişi (Grup 4G) ve PAI-15G/5G Polimorfizmi saptanan 59 kişi (Grup 5G) çalışmaya dâhil edildi. Her grupta olguların vücutkitle indeksi, yaş, cinsiyet, kan basıncı, HDL, LDL, trigliserid ve total kolesterol düzeyleriaraştırıldı. Elde edilen veriler istatistiksel olarak değerlendirildi. Bulgular. Gruplar yaş, cinsiyet,vücut kitle indeksi ve kan basıncı yönünden benzerdi. HDL yönünden gruplar arasındaki farkönemsiz bulundu. Ancak, LDL (p=0.01), trigliserid (p=0.001) ve kolesterol (p=0.02) Grup 4Gdeanlamlı olarak yüksek bulundu. Sonuç. PAI-1, aynı enzimin değişik doku ve organlar üzerindekietkilerinin ne kadar karmaşık ve beklenmedik olabileceğinin karakteristik biyolojik bir örneğidir.Bizim bulgularımız PAI-1 gen 4G/4G polimorfizminin sağlıklı Türk popülasyonunda yüksek LDLve trigliserid düzeyleri ile ilişkili olabileceğini desteklemektedir. Bu nedenle, hiperlipidemikpopülasyonda PAI-1 geninin değerlendirilmesi bu hastalığın prognozu ve etiyolojisinin açığaçıkarılması konusunda yardımcı olabilir.

PAI-1 4G/4G genp olimorf izmi Türk p op ülasyonunda yüksek serum lip id düzeyleri ile ilişkilidir.

Aim. PAI-1 gene is a member of prothrombotic gene group. The 4G allele of the PAI-1 4G/5Gpolymorphism is associated with higher plasma levels of PAI-1 and increase the risk forthrombosis. Besides, there are some studies in the literature claiming an association between the4G allele and the atherogenic lipid profile in certain populations. However, there is no detailedinformation about the effect of 4G on lipid levels in Turkish population. In this study, we aimed toinvestigate correlation between the PAI-1 4G/4G gene polymorphism and plasma lipid levels inhealthy Turkish subjects. Method. Medical genetic department and hospital database were used inthis retrospective study. Over 55 years old subjects were excluded. None of these subjects wasreceiving any type of medication. Fifty subjects (Group 4G) which had isolated 4G/4Ghomozygote PAI-1 gene polymorphism and 59 subjects (Group 5G) which had normal (5G/5G)PAI-1 gene variant were included in the study. Body mass index (BMI), age, sex, blood pressure(BP), high-density lipid levels (HDL), low-density lipid levels (LDL), triglyceride and cholesterollevels were investigated in each group. Obtained data were evaluated statistically. Results. Thegroups were similar about age, sex, BMI and BP. The difference was not significant between eachgroups, were compared for HDL. However, the levels of LDL (p=0.01), triglyceride (p=0.001) andcholesterol (p=0.02) were significantly higher in Group 4G. Conclusions. PAI-1 is a characteristicbiological example of how complicated and unpredictable could be the influence of the sameenzyme on different tissues or organs. Our findings suggest that the 4G/4G polymorphism of thePAI-1 gene might be associated with higher serum of LDL and triglyceride in healthy Turkishpopulation. Therefore, evaluation of the PAI-1 gene in hyperlipidemic population will help clarifyetiology and prognosis of the disease.

PDF

___

1. Pérusse L, Rice T, Després JP, Bergeron J, Province MA, Gagnon J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C. Familial resemblance of plasma lipids, lipoproteins and postheparin lipoprotein and hepatic lipases in the HERITAGE Family Study. Arterioscler Thromb Vasc Biol 1997; 17: 3263-9
2. Stiko A, Hervio L, Loskutoff DJ. Plasminogen activator inhibitors. In: Colleman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia: Pa: Lippincott Williams and Wilkins; 2001; pp: 975-1002.
3. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-63.
4. Boncoraglio GB, Bodini A, Brambilla C, Carriero MR, Ciusani E, Parati EA. An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke. Cerebrovasc Dis 2006; 22: 191-5.
5. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J 1998; 19: 39-43.
6. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
7. Klinger KW, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielsen LS, Stuart N, Stanislovitis P, Watkins P, Douglas R, et al. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 1987; 84: 8548-52.
8. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45
9. Eriksson P, Kallin B, van 't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995; 92: 1851- 5.
10. Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 2008; 122: 736-42.
11. Brown NJ, Murphey LJ, Srikuma N, Koschachuhanan N, Williams GH, Vaughan DE. Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. Arterioscler Thromb Vasc Biol 2001; 21: 1071-7.
12. Sartori MT, Vettor R, De Pergola G, De Mitrio V, Saggiorato G, Della Mea P, Patrassi GM, Lombardi AM, Fabris R, Girolami A. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance. Thromb Haemost 2001; 86: 1161-9.